

CLEMENT MED LIFE SOLUTIONS PVT. LTD.

3G608/Awho/Gurjinder Vihar, Greater Noida 201310

(Previously Anupam Lifescience Pvt. Ltd.)

Mob. 7505441858 www.clementmedlife.com



Product Details

Say no to painkiller tablets

**Long acting painkiller Topical
Ointment**

(Provides pain relief 8 to 15 hrs)

AH-OsteOint (tm)

(Previously AH-Osteocare)

INDEX

S.NO	ITEM	CONTENT	PAGE
1.	ABOUT PRODUCT		02-24
	(AH-OSTEOCAE:www.ah-Osteocare.in)	INTRODUCTION	02-02
		INDEX	03-03
		A. ABOUT PRODUCT	04-05
		B. GLOBAL MARKET VALUATION	06-06
		C. PHASE 2 CLINICAL TRIAL FOR FILING PATENT	07-09
		D. TESTIMONIAL OF PHASE 2 TRIAL	10-17
		E. LICENSING (3 RD PARTY MANUFACTURING LICENSE ISSUED BY DIRECTORATE OF AYUSH)	18-22
		F. OUT SIDE INDIA TRIAL	23-24
2.	ABOUT PATENTS		25-79
		INTRODUCTION	25-25
		INDEX	26-26
		A. PCT DOCUMENTS	27-33
		B. INDIAN P. FILING DOCUMENTS	34-34
		C. US P. FILING DOCUMENTS	35-43
		D. CANADA P. FILING DOCUMENTS	44-54
		E. EUROPE P. FILING DOCUMENTS	55-59
		F. AUSTRALIA P. FILING DOCUMENTS	60-62
		G. NEWZEALAND P. FILING DOCUMENTS	63-64
		H. JAPAN P. FILING DOCUMENTS	65-66
		I. SOUTH AFRICA P. FILING DOCUMENTS	67-71
3.	CRO CLINICAL EVALUATION/PHASE 3 TRIAL/CLAIM VERIFICATION	AGREEMENT WITH SYNCORP HEALTH	25C-25C & 72-72
4.	PRESENT STATUS OF COMPANY/RESERCH HOUSE/PRODUCT-PRODUCTS/INVESTMENT OPPORTUNITY	BRIEF DOCUMENT	25D-25D & 73-76
5.	INVESTMENT	COMPANY VALUATION DETAILS	25D-25D & 25E-25E
6.	ABOUT CHAIRMAN	RESUME	77-79



CIN:-U74900ON2014PTC152978

ANUPAM

LIFE SCIENCES PVT. LTD.

Marketing Division of Anupam Herbals

Anupam Herbals
www.anupamherbalsindia.com
Imp.Exp.Code(IEC) - 0504040936
GSTIN:09ADGPG5071N2Z6

To Whom It May Concern,

Date: June 3, 2020

Subject: Proposal For Research Product AH-Osteocare Ointment

This letter is in regards to the business proposal for marketing of AH Osteocare, a long acting painkiller ointment developed for Osteoarthritis of the knee. Researched and formulated by Anupam Herbals India - Research House of ALS, AH Osteocare is a non-competitive product that also works to provide relief in other painful conditions such as strains, sprains, frozen shoulder, cervical spondylitis, and tension headaches.

Osteocare is effective for as long as 6 to 8 hours a day from the time of application, freeing the patients from the use of any additional oral painkillers and enabling them to live a comfortable pain-free life.

The product has been in-licensed by Anupam Life sciences for global marketing purposes with plans to start with The Republic of India. To understand the opportunity offered by the product, the Indian market for painkiller ointment is estimated at \$550 Million (INR 4,200 Cr). Global statistics indicate a bigger opportunity with the topical painkiller market valued at \$7.8 Billion and the market for treatment for Osteoarthritis at \$6.8 Billion.

Anupam Life Sciences is looking for a marketing partner to scale the product and reach millions of people to enable people suffering from pain to live a pain - free life. The type of marketing agreement is open to negotiation and ALS will consider all proposals with careful due diligence. Additionally, at fair market valuation, ALS is also open to an agreement involving a complete technology transfer.

Siddharth Gupta
Chief Operating Officer
Anupam Life Sciences

Address : 3G-608 AWHO/GURJINDAR VIHAR GREATER NOIDA(201310)U.P
Mobile:- +917505441858

Email:- info@anupamlifesciences.in, www.anupamlifesciences.in

INDEX

S.NO	ITEM	CONTENT	PAGE
1.	ABOUT PRODUCT		02-24
	(AH-OSTEOCAE:www.ah-Osteocare.in)	INTRODUCTION	02-02
		INDEX	03-03
		G. ABOUT PRODUCT	04-05
		H. GLOBAL MARKET VALUATION	06-06
		I. PHASE 2 CLINICAL TRIAL FOR FILING PATENT	07-09
		J. TESTIMONIAL OF PHASE 2 TRIAL	10-17
		K. LICENSING (3 RD PARTY MANUFACTURING LICENSCE ISSUED BY DIRECTORATE OF AYUSH)	18-22
		L. OUT SIDE INDIA TRIAL	23-24

AH-Osteocare

A Long Acting Painkiller Ointment

About the Product:

AH-Osteocare Ointment is an Ayurvedic preparation and its formulation is based on ancient Ayurvedic therapy of India. The treatment is a boon to our geriatric society because it provides a pain-free life from knee osteoarthritis without the use of any oral medicine (after 7 days painkiller can be removed).

Osteocare ointment penetrates the skin to reduce knee pain for a long duration similar to that of an Oral painkiller. While the ointment was specifically invented to treat knee pain, it can be used in place of other tropical painkillers.

Application and Effectivity:

Osteocare is effective for as long as 6 to 8 hours a day from the time of application, freeing the patients from the use of any additional oral painkillers and enabling them to live a comfortable pain-free life.

- It is applied gently on the skin over the affected area to facilitate penetration.
- In case of knee pain, it is applied around the knee including the outer, inner, front and the back sides in intervals of 6 hours. Also, applied before and after sleep.
- Over time, its effectiveness increases to 24 hours even when applied once or twice a day.
- If required and prescribed by the doctor, oral painkillers can be used along with Osteocare without any drug interactions.

Composition:

Each 50g contains: rasna patria 8%, Arandi beej 3%, Haldi 10%, gandhpura tel 3%, tarpin tel 1%, niligiri tel 2%, Nirgindi oil 1%, katuvera oil 1%, menthol 3%, Permissible base material excipients/additives to make q.s Methyl salicylate, carbopol-940, glycerin, Di-EDTA, tea, bht, emulsifying wax, cetyl alcohol, water

AH-OSTEOCARE

HOW TO USE OINTMENT

It is developed for the relief of knee pain from old age. After using it twice daily for some days, it begins to provide 24 hours of relief which may even extend to 2 to 3 days.

During the initial period of application, some people report having benefited for 8 to 12 hours from the first day itself whereas some others only experience relief for 3 to 4 hours. However, with continuous use of 7 to 10 days, the relief in knee pain goes upto 6 to 8 hours or more.

How to use:- Apply the ointment around the knee. Re-apply whenever there is pain or after 6 hours, whichever is sooner, even if there is no pain. It is **MUST** be apply at night before going to bed even if it has been 1 hour since last application so it can work overnight. Next, AH Osteocare should be applied as soon as you wake up in the morning.

Keep applying the ointment this way over and over again for 7 to 10 days. After this period, even an application of the ointment twice or thrice a day will provide 24 hours of relief. After using the AH-Osteocare for only a day after two to three months, the relief starts lasting for two or three days as well.

Note(1):- This Ointment affects different people differently. In patients with early knee pain which has not been from long time, the need for ointment decreases with time and until the need for this ointment decreases to minimal use or only in rare circumstances.

The ointment doesn't eradicate the problem or cure the disease but it provides relief from pain that is generated as knee pain due to old age . To cure this disease, kindly consult an Orthopedic doctor.

Note(2):- AH-Osteocare ointment has been created for the knee pain of old aged people (Osteoarthritis), However, this ointment can be used for other pains originating in other body parts as well, such as for the neck pain, back pain, etc.

Note(3):- Renal patients, who are on dialysis, cannot take oral painkillers due to side effects that impact kidneys. In such cases, through the external application of the ointment, patients are able to reduce and, over time, eliminate their dependency on oral painkillers and gain long lasting relief.

Note(4):- In cases where the pain is psychosomatic, painkillers are not prescribed due to their inefficacy and the use of sedatives is required. AH-Osteocare ointment is effective in such cases as well without requiring the use of painkillers or sedatives to provide long term relief from pain.

Note(5):- Ladies patients, who are on Pregnant, cannot take oral painkillers due to side effects that impact Foetus (baby). In such cases, through the external application of the ointment, patients are able to reduce and, over time, eliminate their dependency on oral painkillers and gain long lasting relief In their lower back and other musculoskeletal pains.

Note(6):- Young children, who are very active, cannot take oral painkillers due to side effects that impact growth. In such cases, through the external application of the ointment, children are able to reduce and, over time, eliminate their dependency on oral painkillers and gain long lasting relief in night cries (tibial pain during night). This way without oral painkiller, children can sleep whole night without leg pain.

Note(7):- Young people, who are complaining frequent headaches, Will take too much oral painkillers. In such cases, through the external application of the ointment, patients are able to reduce and, over time, eliminate their dependency on oral painkillers and gain long lasting relief In headache without oral tablets.

Product marketed in india by:

Clement Med Life Solutions Pvt. Ltd.
(www.clementmedlife.com)

Market size:**Local Painkiller Ointment**

The market size for pain balms in India is valued at USD 550 Million (INR 4,200 Cr) in 2019 which includes all forms of products in cream, gel, spray and balm. RB has partnered the government's Fit India Movement to raise awareness on growing new age lifestyle pains

Globally, the market size for local painkillers was estimated to be USD 7.8 Billion in 2017. This market is projected to grow to USD 13.3 Billion by 2025 registering a CAGR of 7.4% between 2018-2025.

Osteoarthritic therapeutics market:

The osteoarthritis therapeutics market is expected to grow from USD 6.8 billion in 2019 to reach USD 10.1 billion by 2024, at a CAGR of 8.1%

In 2018, while Europe accounted for the largest share of the global market, the APAC region is the fastest growing osteoarthritis therapeutics market

Additionally, the knee segment of the market accounted for the largest share in the 2018 and is expected to experience the highest growth over the forecast period globally due to a large number of patients suffering from knee osteoarthritis.

Sources

Allied Market Research "*Topical Pain Relief Market*"
Markets and Markets "*Osteoarthritis Therapeutics Market*"

Transactions (PHASE 2 CLINICAL TRIAL FOR FILING PATENT)

The transaction sheet below lists the amount of orders (in pieces) that were placed by doctors and fulfilled by Anupam Life Sciences in July, 2019.

Total pieces shipped to Doctors - 1,422

Transaction Sheet for Osteocare Ordered by Physicians				
Currency - India Rupee (INR)				
S.NO	DATE	Ordering Physician	Village	Pieces Ordered
1	1/7/2019	DR. ASHOK BHATI	SIRSA	10
2	11/7/2019	M.D MEDICAL STORE	DANKAUR	20
3	11/7/2019	DR KRASHAN VEER HOSPITAL	DANKAUR	20
4	11/7/2019	HASAN MEDICAL STORE	DANKAUR	20
5	11/7/2019	DR. JAYVEER KHAREI	DANKAUR	20
6	11/7/2019	DIKSHA MEDICAL STORE	DANKAUR	20
7	11/7/2019	AMIT MEDICAL STORE	DANKAUR	20
8	11/7/2019	AVANTIKA HOSPITAL	DANKAUR	25
9	11/7/2019	DR.RAKESH (DHANORI BALE)	DANKAUR(MALLAPUR RODE)	25
10	11/7/2019	SHARMA MEDICAL STORE	DANKAUR (STATION)	20
11	11/7/2019	BHATI MEDICAL STORE	DANKAUR (STATION)	5
12	11/7/2019	ANIL MEDICAL STORE	DANKAUR (STATION)	10
13	11/7/2019	DR. ASHUTOSH	GHARBHARA	50
14	11/7/2019	DR.TEJVEER BHATI	CHUHARPUR	50
15	11/7/2019	DR. VINOD	AJAYPUR (STATION)	50
16	11/7/2019	DR.DHARVENDAR	GHORI BACHEDA	50
17	11/7/2019	DR. SHREECHAND (ABHI CLINIC)	BILASPUR(G.NOIDA)	25
18	11/7/2019	DR. YOGENDRA SHARMA	BILASPUR(G.NOIDA)	30
19	11/7/2019	JAVED KHAN	BILASPUR(G.NOIDA)	25
20	11/7/2019	E.D. KHAN	KARASI(G.NOIDA)	25
21	11/7/2019	DR.ASHOK	ATTA	25
22	12/7/2019	BHOOME STAR	SIRSA	25

23	12/7/2019	TIVARI PHARMA	DANKAUR	25
24	12/7/2019	DR. DEEPU BANGALI	LOOKSAR	25
25	12/7/2019	DR. PARVINDRA PAL	LOOKSAR	25
26	12/7/2019	DR.RAJU	DEVLA	25
27	12/7/2019	DR.S.S CHOUDHARY	DEVLA	10
28	12/7/2019	DR.M.S SINGH	DEVLA	5
29	12/7/2019	DR. MUKESH	TUGLPUR	50
30	12/7/2019	NEW MUSKAN MEDICAL	TUGLPUR	20
31	12/7/2019	DR.RAJEEV	KONDLI	10
32	12/7/2019	DR. SUSHANT	KONDLI	10
33	12/7/2019	DR. AMIT	KONDLI	20
34	12/7/2019	DR.SANJAY	SALARPUR	5
35	12/7/2019	SHIFA CLINIC	MIRZAPUR	10
36	12/7/2019	DR. HARENDERA	GHANORI	25
37	12/7/2019	DR. BALVEER	JUNEDPUR	25
38	12/7/2019	DR. NIKHIL (HANI CLINIC)	SIKANDRABAD	60
39	13/07/19	DR. SAGAR	KONDLI	30
40	13/07/19	SUMIT MEDICAL STORE	HALDONI(G. NOIDA)	25
41	13/07/19	DR.MIRAJ KHAN	HALDONI(G. NOIDA)	25
42	13/07/19	RANA MEDICAL	HALDONI(G. NOIDA)	25
43	13/07/19	DR.RIZVAN	SUTTYANA(HALDONI)	10
44	13/07/19	DR.AMIT KUMAR RAO	SUTTYANA(HALDONI)	10
45	14/07/19	BHATI MEDICAL STORE	TUGLPUR	25
46	14/07/19	DR. K.P RAY	BRONDEE	25
47	15/07/19	DR. VIKASH RAY	SIRSA	10
48	15/07/19	DR. S.N PHARMA	SIRSA	25
49	15/07/19	MAA BHAGAVATI MEDICAL	SIRSA	25
50	15/07/19	DR.RAHEESH KHAN	GHORI BACHEDA	25
51	15/07/19	DR.MANEESH RAO	GHORI BACHEDA	10
52	15/07/19	NAVEEN MEDICAL STORE	GHANGOLA	10
53	15/07/19	DR. AMAR	DADUPUR	25
54	15/07/19	DR. BHARAMJEET SINGH	DADUPUR	10
55	15/07/19	DR. CHAND KHAN	BAAGPUR	2
56	15/07/19	DR. N.K VISHVAS	SALEMPUR	5
57	16/07/19	DR. SABIR ALII	DANKAUR	25
58	16/07/19	DR. RAJ SHARMA	ACCHER(G.NOIDA)	25

59	17/07/19	DR. S.K BHATI	GHORI BACHEDA	25
60	17/07/19	DR. VENEETA HOSPITAL	GHORI BACHEDA	30
61	17/07/19	DR. RAHUL KHAN	TUGLPUR	15
62	17/07/19	DR.RANVEER	KASANA	10
63	18/07/19	DR.SATPAL SINGH	KASANA	10
64	18/07/19	DR. T.K BHATI	KASANA	10
65	18/07/19	BHATI MEDICAL STORE	MANEESH	30
Total Number of Pieces Ordered in July				1,422

Testimonial - Trials Conducted by ALS

1. Rahul Sharma - Greater Noida
Mobile - 7532091205



ANUPAM
LIFE SCIENCES PVT. LTD.
GSTIN: 09ADGPG5071N2Z6



मैं राहुल शर्मा मोबाइल नंबर +917532091205 मैं अनुपम लाइफ साइंसेज में जॉब करता था। मैं मनीष और रमेश के साथ डॉक्टरों व मेडिकलों पर अपने मलहम (AH-OSTEOCARE) बड़े उम्र के घुटने के गठिया के दर्द में प्रयोग करके दिखाता था। हमने लगभग डेढ़ से दो महीने के दौरान 50 से 60 डॉक्टरों के पास संपर्क किया था। सभी स्थानों से संतोष जनक परिणाम मिले लेकिन कुछ मरीजों पर परिणाम नहीं मिले। इसलिए हम एक डॉक्टर के पास चार पांच मरीजों पर ट्रायल किया करते थे और ज्यादातर मरीजों में आराम हो जाता था। यदि किसी को दिल्ली एनसीआर (DELHI NCR) में ट्रायल करना हो। एवं ट्रायलो के बारे में जानकारी देने में मदद कर सकता हूँ। और जो डॉ हमारी दवाई का प्रयोग कर रहे हैं उनकी सूची दे दी गयी है और ज्यादा जानकारी के लिए मुझसे संपर्क कर सकते हैं।

राहुल शर्मा
7532091205
ग्रेटर नोएडा (U.P)

Address : 3G-608 AWHO/GURJINDAR VIHAR GREATER NOIDA(201310)U.P

Mobile:- +917505441858

Email:- info@anupamherbalsindia.com, www.anupamlifesciences.com

English translation page - 10

I am Rahul Sharma. Mobile Number: +91 7532091205. I used to work for Anupam Life sciences.

With Manish and Ramesh, I used to present the applications of the AH- OSTEOCARE tubes to doctors and pharmacies by applying them on old aged people with osteoarthritis problems in the knee. In about 2 - 3 months, we contacted approximately 50 - 60 doctors. We received a positive response from almost all the places except for a few. This is why we used to conduct trials on 5 - 6 patients per doctor and most of the time they would feel relief from the pain. In case someone would like to conduct trials in Delhi NCR, I can help provide information regarding the trials stated above.

And the information regarding the doctors that were using the medicines have already been provided. For more information, you can get in touch with me

Rahul Sharma

7532091205

Greater Noida (U.P.)



ANUPAM
LIFE SCIENCES PVT. LTD.
GSTIN: 09ADGPG5071N2Z6



मेरा नाम प्रमोद मिश्रा मोबाइल नंबर 09412800645 मेरी उम्र 60 साल है। मेरे घुटने में दर्द होता था। मैं जब पूजा करने के लिए पाल्ती मारकर बैठता था तो ज्यादा देर तक नहीं बैठ पाता था। डॉ अनुपम गुप्ता द्वारा (AH-OSTEOCARE) मलहम दिन में दो बार लगाने को दिया। 1 सप्ताह के बाद तीन से 4 घंटे तक आराम से पाल्ती मार कर पूजा करने लगा और 24 घंटे दर्द में आराम रहने लगा।

मेरी साली जो लगभग 55 वर्ष की है, उनके घुटने में गठिया का दर्द था। उन्हें पैरों को मोड़ते समय बहुत दर्द होता था और मैंने उन्हें भी यह (AH-OSTEOCARE) मलहम इस्तेमाल करने को दिया और उन्हें भी काफी फायदा पहुंचा। लेकिन अभी भी वह जमीन पर नहीं बैठ पाती हैं, लेकिन सीढ़ियों पर चढ़ सकती हैं। पहले वह प्रतिदिन दर्द की गोली खाती थी। (AH-OSTEOCARE) मलहम के इस्तेमाल के बाद दर्द की गोली कभी कभी खानी पड़ती है।

प्रमोद मिश्रा
09412800645
शिव पुरम बदायूँ (U.P)

Address : 3G-608 AWHO/GURJINDAR VIHAR GREATER NOIDA(201310)U.P

Mobile:- +917505441858

Email:- info@anupamherbalsindia.com, www.anupamlifesciences.com

English translation page - 12

My name is Pramode Mishra. Mobile number: 09412800645. I am 60 years old. I used to feel pain in my knee. When I used to fold my legs while sitting down to pray, I wouldn't be able to sit for long durations. Dr. Anupam Gupta gave me a medicine (AH - OSTEOCARE) to apply twice a day. After a week, I was able to sit for 4 hours during my praying sessions and had a relief from pain for as long as 24 hours.

My sister-in-law, approximately 55 years old, was suffering from Osteoarthritis. She used to feel extreme pain while folding her legs and I gave the same medicine (AH- OSTEOCARE) to her for the use and she also found it to be quite useful. But even now she can't sit on the floor, but she can climb the stairs. Earlier, she used to consume painkillers on a daily basis. After the use of (AH-OSTEOCARE) medicine, we rarely consume painkillers.

Pramod Kr Mishra

09412800645

Shivpuram Budaun U.P.)

B

3. Satyendra Gautam - Budaun
Mobile - 7017293966



ANUPAM
LIFE SCIENCES PVT. LTD.
GSTIN: 09ADGPG5071N2Z6



मेरा नाम सत्येंद्र गौतम है। मेरी माता जी 50 साल की हैं जिनके घुटने में दर्द रहता है। उनको (AH-OSTEOCARE) मलहम लगाने को दिया। शुरुआत में मलहम लगाने पर थोड़ी देर बाद दर्द होने लगता था। और मलहम फिर से लगाना पड़ता था। 24 घंटे आराम के लिए मलहम को चार से पांच बार लगाना पड़ता था। तीन से चार महीने बाद दिन में एक या दो बार मलहम लगाते हैं जब भी जब भी दर्द होता है और कम से कम 3 दिन तक आराम रहता है और दर्द की कोई गोली नहीं लेनी पड़ती है। यह दर्द का बहुत अच्छा मलहम लगा। लेकिन मर्ज को यह खत्म नहीं करता है। सिर्फ दर्द को ही खत्म करता है।

सतेन्द्र गौतम
जिला बदायूँ (U.P)
7017293966

Address : 3G-608 AWHO/GURJINDAR VIHAR GREATER NOIDA(201310)U.P
Mobile:- +917505441858
Email:- info@anupamherbalsindia.com,www.anupamlifesciences.com

A

English translation page - 14

My name is Satendra Gautam. My mother is 50 years old and feels a constant pain in the knee. She was given AH- Osteocare ointment for application. Initially, the effect of applying the ointment would last only for a few hours and would need for us to apply again. For a 24 hour relief, we would have to apply for it 4-5 times. After 3-4 months, we only apply the ointment once or twice a day or whenever we feel the pain, the relief would last for at least 3 days without any consumption of oral painkillers. This is an excellent ointment. But, this only provides relief from pain and does not cure the problem forever.

Satendra Gautam

Distt Budaun (U.P)

7017293966

B

4. Shalendra Singh - Moradabad
Mobile - 9027529467



ANUPAM

LIFE SCIENCES PVT. LTD.

GSTIN: 09ADGPG5071N2Z6



INDIA

मेरा नाम शैलेंद्र सिंह है। मेरा मोबाइल नंबर 9027529467 है मैं अनुपम लाइफ साइंसेज में मार्केटिंग मैनेजर था। मेरे अंडर में तीन एम आर (M.R) काम करते थे, जोकि (मुरादाबाद, बरेली, रामपुर और शाहजहांपुर) में पोस्टेड थे। यह (AH-OSTEOCARE) मलहम जो कि घुटने के गठिया की दवा है, मैं उसका डाक्टरों को ट्रायल करके दिखाता था। ज्यादातर डॉ बहुत संतुष्ट थे। कोरोना की वजह से डॉक्टरों की सूची और डॉक्टर से लिखवा कर नहीं दे पा रहा हूं। जैसे ही कोरोना खत्म होगा। तभी डॉक्टरों की जानकारी और दवा का अनुभव उन से लिखवा कर अनुपम लाइफ साइंसेज को दे दीया जायेगा ।

शैलेंद्र सिंह
लीलौर (U.P)
9027529467

Address : 3G-608 AWHO/GURJINDAR VIHAR GREATER NOIDA(201310)U.P

Mobile:- +917505441858

Email:- info@anupamherbalsindia.com, www.anupamlifesciences.com

A

English translation page - 16

I am Shalandra singh. My mobile number is 9027529467. I was the marketing manager in Anupam life sciences. Under me there were three medical Representatives who visited Rampur/Bareilly/moradabad and Shahjahanpur. My work is to demonstrate the effect of AH-Osteocare medicine which is used in Oseto- arthritis of knee joint to the doctors. Most of the doctors were very satisfied. Due to Covid19, I am unable to provide the list of doctors and their written experience regarding the medicine. As soon as the effect of covid 19 ends, I will submit the list of doctors and their written experiences to Anupam Life sciences.

Shalandra Singh
LEELA (U.P)
9027529467

B

प्रेषक,

लाइसेंसिंग अधिकारी,
आयुर्वेदिक एवं यूनानी सेवाएँ,
उत्तराखण्ड, देहरादून।

सेवा में

मैसर्स हंस हर्बल्स प्रा० लि०
प्लॉट नं० 59-60, सेक्टर 8ए,
सिडकुल हरिद्वार।

संख्या- 6/SS-SC/डी-557/2019-20

दिनांक 22 जुलाई, 2019

विषय-

अतिरिक्त योगों के निर्माणार्थ अनुमति दिये जाने के सम्बन्ध में।

महोदय,

उपर्युक्त विषयक आपके पत्र दिनांक 21.06.2019 के साथ प्राप्त

- | |
|-----------------------------|
| 1- AYUR SHAKTI(CHOCOLATE) |
| 2- AYUR SHAKTI(KESAR-PISTA) |
| 3- ANTI DANDRUFF SHAMPOO |
| 4- GOLD FACE WASH |
| 5- AH-OSTEOCARE |

अतिरिक्त औषधियों की सूची इस पत्र के साथ
संलग्न करते हुए निवेदन है कि औषधि
नियंत्रक/लाइसेंसिंग अधिकारी, आयुर्वेदिक एवं
यूनानी सेवाएँ उत्तराखण्ड, देहरादून द्वारा

प्रेषित औषधि निर्माणार्थ लाइसेंस संख्या UK.AY.362/2017 में उल्लिखित शर्तों एवं प्रतिबन्धों
के अधीन क्रमांक 01 से क्रमांक 02 पर अंकित योगों को आयुर्वेदिक बल्यपोषक, क्रमांक 03
से क्रमांक 04 पर अंकित योगों को आयुर्वेदिक सौन्दर्य प्रसादक एवं क्रमांक 05 पर अंकित
योग को आयुर्वेदिक औषधि के रूप में निर्माण करने की अनुमति प्रदान की जाती है।

भवदीय

(डॉ० यतेन्द्र सिंह रावत)
लाइसेंसिंग अधिकारी

संख्या एवं दिनांक तदैव।

प्रतिलिपि-औषधि निरीक्षक/जिला आयुर्वेदिक एवं यूनानी अधिकारी हरिद्वार को उक्त की
एक प्रति इस पत्र के साथ संलग्न करते हुए सूचनार्थ एवं आवश्यक कार्यवाही हेतु प्रेषित।

(डॉ० यतेन्द्र सिंह रावत)
लाइसेंसिंग अधिकारी

Hans Herbals Pvt.Ltd.

Plot.No.-59,60 Sector-8A Sidcul Haridwar-249403

Name: AH - OSTEOCARE

Herbal TOPICAL Preparation for External Use

License No.- UK.AY-362/2017

Category: Ayurvedic Proprietary Medicine

50g contains:

No.	Ingredient Name	Latin/English Name	References & Page No.	Classical Therapeutic	Qty. (%)	Part Used
1	Rasna Patra	Pluchea lanceolata	Bh.Pr.Ni.-76	Sthanik Shoth Vedna Har,	8.00	Leaf LE
2	Arand Beej	Ricinus communis	Bh.Pr.Ni.-286	Dah Shamak , Vatik Rog Har	3.00	Seed LE
3	Haldi	Curcuma Longa	Bh.Pr.Ni.-491	Sthanik Vedna Har, Vishaghna	10.00	Rhizome LE
4	Gandhpura Oil	Gaultheria fragrantissima	Bh.Pr.Ni.-809	Aam Vat Har,Shoth Har	3.00	Whole Plant
5	Tarpin Oil	Pinus longifolia	Bh.Pr.Ni.-189	Sandhi Soth Har,Vedna Har	1.00	Resin
6	Eucalyptus Oil	Eucalyptus globulus	Bh.Pr.Ni.-804	Pratidushak,Aam Vat Har, Shoth Har	2.00	Leaf
7	Katuvira Oil	Capsicum annum	Bh.Pr.Ni.-810	Vatik Peeda Har	1.00	Fruit
8	Manthol	Mentha peperata	Bh.Pr.Ni.-806	Sthanik Sangya Har	3.00	Leaf Ext.
Permissible Base Material and Excipients/Additives:						
9	Methyl Salicylate	As Excipients	As per rule 169,Permitted Excipients of D & C Act,1940/IP/PFA	11.50	Permitted Exipients as per IP	
10	Carbopol 940	Gelling Agent		1.00		
11	Glycerine	Plasticizer		2.50		
12	DI-EDTA	Chelating Agent		0.10		
13	Tri ethanol amine	Ph Maintainer		0.20		
14	BHT	Thickening Agent		0.10		
15	Bee Wax	Emulsifying Agent		2.50		
16	Emulsifying Wax	Emulsifying Agent		3.50		
17	Cetyl Alcohol	Solubling Agent		2.50		
18	Purified Water (DM Water)			45.10		

IP-Indian pharmacopeia , PFA- Prevention of Food Adulteration Act, Bh.Pr.Ni.- Bhav Prakash Nigam

IP-Indian pharmacopoeia , PFA- Prevention of Food Adulteration Act, Bh.Pr.Ni.- Bhav Prakash Nighantu

Indications: Useful in osteoarthritis . Also effective in other inflammatory & painful conditions of joints.

Directions for use: To be massaged gently on the skin over affected area so as to facilitate penetration.

Storage: Store in cool and dry place.

Expiry: 36 months from the date of manufacturing.

Packing Size: 10/ 20/50/60/70/90/100/120/150/200/250/300/500/100 g Pack Size.

Manufacturing Process: All water phase ingredients are dissolved in DM water one by one with stirring continuously and all active ingredients are mixed with stirring at room temperature.



Licensing Authority
Ayurvedic & Unani Services
Uttarakhand, Dehradun

For Hans Herbals Pvt. Ltd.
Authorised Signatory

**Office Of The
Director, Ayurvedic and Unani services
Uttarakhand, Dehradun**

Letter No. ⁷⁴⁹¹⁻⁹²...../D-555/2017-18

Date ²⁸⁻⁰⁷⁻²⁰¹⁷.....

G.M.P CERTIFICATE

Form – 26E-I

(See rule 155-B)

(Certificate of Good Manufacturing Practices (GMP) to Manufacturer of
Ayurveda, Siddha or Unani Drugs)

Certified that Manufacturing unit licensee, namely M/s
HANS HERBALS PVT. LTD, P.NO- 59-60, SECTOR-8A, IIE, SIDCUL,
HARIDWAR State- UTTARAKHAND License No UK.AY- 362/2017 comply
with the requirements of Good Manufacturing Practices (GMP) of Ayurveda,
Siddha or Unani Drugs as laid down in schedule T of the Drug & Cosmetic
Rules 1945.


This Certificate is valid from **29-07-2017** to **28-07-2022**.

Place : Dehradun

(Dr. V.K Sharma)
Licensing Authority

Letter No and Date as above.

**Copy to- Drug Inspector /District Ayurvedic and Unani Officer Haridwar for
information and necessary action.**



(Dr. V.K Sharma)
Licensing Authority

Form 25-D
(See Rule 154)

Licence to manufacture for sale of Ayurvedic
(Including Siddha) or Unani drugs

No. of license- **UK.AY- 362/2017**

1. **M/s HANS HERBALS PVT. LTD** is/are hereby licensed to manufacture the following Ayurvedic (Including Siddha) or Unani drugs on the premises situated at **P.NO- 59-60, SECTOR-8A, IIE, SIDCUL, HARIDWAR State- UTTARAKHAND** Under the direction and supervision of the following technical staff.

(a). Technical Staff (Name)

- 1- Dr. Vijendra Kumar, BAMS
- 2- Mr. Shailender Kumar, B.Sc

(b) Name of drugs (each item to be separately specified)

- 2. The licence shall be in force from **29-07-2017 to 28-07-2022**.
- 3. The licence is subject to the conditions stated below and to such other conditions as may be specified in the Rules for the time being in force under The Drugs And Cosmetics Act, 1940.



Signature.....

Designation.....

Conditions of Licence

- 1. This licence and any certificate of renewal in force shall be kept on the approved premises and shall be produced on the request of any Inspector, appointed under The Drugs And Cosmetics Act, 1940.
- 2. Any change in the technical staff named in the licence shall be reported forthwith to the licensing Authority.
- 3. This licence shall be deemed to extend to such additional items as the licensee may intimate to the licensing authority from time to time, and as may be endorsed by the licensing authority.
- 4. The licensee shall inform the licensing authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change take place unless, in the meantime, a fresh licence has been taken from the licensing authority in the name of the firm with the changed constitution.



Government of India
And
Government of Uttarakhand
Form GST REG-25

Certificate of Provisional Registration

1.	GSTIN	05AADCH8760J1ZC
2.	PAN	AADCH8760J
3.	Legal Name	HANS HERBALS PRIVATE LIMITED
4.	Trade Name	HANS HERBALS PRIVATE LIMITED
5.	Registration Details under Existing Law	
	Act	Registration Number
(a)	TIN under Value Added Tax	05017311906
Date	28/06/2017	

This is a Certificate of Provisional Registration issued under the provisions of the Act.

Testimonial - Central Asia

МАЪЛУМОТНОМА

Мен доктор Юсупов Акмал Богот туман марказий шифохонасида терапевт шифокор бўлиб ишлайман. Менга дўстим Санжар томонидан Хиндистон давлатида “АН-OSTEOCARE” бренди остида ишлаб чиқарилган оғриқни қолдирувчи маз синаб кўриш учун тақдим қилинди.

Ушбу мазни иккита беморда синаб кўрдим. Синов муддати 5-6 кун давом этди ва самараси сезиларли даражада эканига амин бўлдим. Беморларнинг айтишича олдинга оғриқ кучайиб кейинчалик оғриқ йўқола бошлагани ва 4-5 кундан сўнг ўзларини яхши хис қилганликлари маълум бўлди. Фойдаланиш давомида ножўя таъсирлари сезилмади.

Албатта одатда тиббиёт дори воситалари белгиланган тартибда синовдан ўтказилиши керак, ҳозирда дорихоналарда кўплаб оғриқ қолдирувчи мазларга дуч келамиз. Хар битта бемор дори воситаларини сотиб олишдан олдин қайси давлатда ишлаб чиқарилгани, уларнинг хусусиятлари, зарарли томонлари ва бошқа тарафларига эътибор беришади.

Бугунги кунда Республикамизга кўп турдаги оғриқ қолдирувчи дори воситалари Россия, Украина ва бошқа чет давлатлардан импорт қилинмоқда. Лекин биз “АН-OSTEOCARE” бренди остида ишлаб чиқарилган оғриқни қолдирувчи маз самарали деб ўйлаймиз. Шунга қарамасдан ушбу дори воситасини белгиланган тартибда клиник синовдан ўтказиш лозим.

Юсупов Акмал



06.12.2019 йил

Translation

I work as a therapist doctor in the Central Hospital of Bogot District. It was presented to me by my friend Sanjar for testing the pain reliever maz produced under the brand name "АН-OSTEOCARE" in the state of India.

I tested this Maz on two patients. The test period lasted 5-6 days and I was sure that the effect was noticeable. Patients say that the has been pain in the beginings and after the

pain began to go away, and 4-5 days later it became known that they felt better. Side effects were not noticed during use.

Of course, usually medical drugs need to be tested in the established order, we now face a lot of painkillers in pharmacies. Each patient pays attention to in which state the drugs were produced before the purchase, their properties, their harmfulness and other aspects.

There are lot of imported medicines as pain killer from the Russia, Ukraine and other foreign countries. But we think that "AH-OSTEOCARE" is effective for the Osteoarthritis. Anyway we need more clinical test.

Yusupov Akmal

06.12.2019 year

Introduction

- A. PCT filed in 2021 which covers around 156 countries around the globe. Now individual patent filing starts in around 100 plus countries started with developed nation. Till date company filed patent in INDIA, USA, CANADA, EUROPEON UNION, AUSTRALIA, NEWZEALAND, JAPAN AND SOUTH AFRICA (FILING DOCUMENTS ATTACHED).
- B. UPTO Dec 2023 company is filing patent in all other premium countries like Singapore, Malaysia, Mexico, UAE, Brazil, Philippines, Sri Lanka, Thailand, Myanmar, Vietnam, Cambodia, Indonesia, English speaking African countries via ARIPO, French Speaking African Countries via OAPI, Eurasia, South American countries and Gulf countries.
- C. Company engaged Syncorp healthcare, a CRO organization affiliated with South Korea, for Verification and Authentication of claims of present research product. The clinical trial via authentic CRO is also necessary for regulatory purposes so that Dossier will be compiled to get marketing licenses in different countries around the globe. Presently it is under process.
- D. The present status of company, other research products and investment opportunity as per Company valuation will be described below. (For extended details: please see presentation attached at [read more] with [research house] in [home page] at www.anupamlifesciences.in)
- E. For Investment, complete company valuation report will be provided on request.

INDEX

S.NO	ITEM	CONTENT	PAGE
2.	ABOUT PATENTS		25-79
		INTRODUCTION	25-25
		INDEX	26-26
		J. PCT DOCUMENTS	27-33
		K. INDIAN P. FILING DOCUMENTS	34-34
		L. US P. FILING DOCUMENTS	35-43
		M. CANADA P. FILING DOCUMENTS	44-54
		N. EUROPE P. FILING DOCUMENTS	55-59
		O. AUSTRALIA P. FILING DOCUMENTS	60-62
		P. NEWZEALAND P. FILING DOCUMENTS	63-64
		Q. JAPAN P. FILING DOCUMENTS	65-66
		R. SOUTH AFRICA P. FILING DOCUMENTS	67-71
3.	CRO CLINICAL EVALUATION/PHASE 3 TRIAL/CLAIM VERIFICATION	AGREEMENT WITH SYNCORP HEALTH	25C-25C & 72-72
4.	PRESENT STATUS OF COMPANY/RESERCH HOUSE/PRODUCT-PRODUCTS/INVESTMENT OPPORTUNITY	BRIEF DOCUMENT	25D-25D & 73-76
5.	INVESTMENT	COMPANY VALUATION DETAILS	25D-25D & 25E-25E
6.	ABOUT CHAIRMAN	RESUME	77-79

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference SR20202110854		FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/IN2021/050722	International filing date (day/month/year) 23-07-2021	(Earliest) Priority Date (day/month/year) 09-06-2021	
Applicant GUPTA, ANUPAM			

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed.
☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

b. ☐ This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).

c. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (see Box No. II).

3. ☐ **Unity of invention is lacking** (see Box No. III).

4. With regard to the **title**,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant.
☐ the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. _____
☐ as suggested by the applicant.
☐ as selected by this Authority, because the applicant failed to suggest a figure.
☐ as selected by this Authority, because this figure better characterizes the invention.
- b. ☐ none of the figures is to be published with the abstract.

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

GUPTA, ANUPAM
SINGH, VIVEK SAGACIOUS RESEARCH
PVT. LTD. PLOT NO: B7/B8, SECTOR
32, ECHELON INSTITUTIONAL AREA,
GURGAON, HARYANA, GURGAON-122003
INDIA

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT AND
THE WRITTEN OPINION OF THE INTERNATIONAL
SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing (day/month/year) 26-10-2021	
Applicant's or agent's file reference SR20202110854	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/IN2021/050722	International filing date (day/month/year) 23-07-2021
Applicant GUPTA, ANUPAM	

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

How? Directly to the International Bureau preferably through ePCT, or on paper to:
The International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland

For more detailed instructions, see the *PCT Applicant's Guide*, International Phase, paragraphs 9.004 – 9.011.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.
3. ☐ **With regard to any protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with any request to forward the texts of both the protest and the decision thereon to the designated Offices.
- ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

The applicant may **submit comments on an informal basis on the written opinion of the International Searching Authority** to the International Bureau. These comments will be made available to the public after international publication. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established.

Shortly after the expiration of **18 months from the priority date, the international application will be published** by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau before the completion of the technical preparations for international publication (Rules 90bis.1 and 90bis.3).

Within **19 months** from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase **until 30 months** from the priority date (in some Offices even later); otherwise, the applicant must, **within 20 months** from the priority date, perform the prescribed acts for **entry into the national phase** before those designated Offices. In respect of other designated Offices, the time limit of **30 months** (or later) will apply even if no demand is filed within 19 months. For details about the applicable time limits, Office by Office, see www.wipo.int/pct/en/texts/time_limits.html and the *PCT Applicant's Guide*, National Chapters.

Within **22 months from the priority date, the applicant may request that a supplementary international search be carried out** by a different International Searching Authority that offers this service (Rule 45bis.1). The procedure for requesting supplementary international search is described in the *PCT Applicant's Guide*, International Phase, paragraphs 8.006-8.032.

Name and mailing address of the ISA/ Indian Patent Office Plot No. 32, Sector 14, Dwarka, New Delhi- 110075 Facsimile No.	Authorized officer Suresh Kumar Telephone No. +91-1125300200
---	---

FORM 1 THE PATENTS ACT 1970 (39 of 1970) & THE PATENTS RULES, 2003 APPLICATION FOR GRANT OF PATENT <i>[See section 7, 54 & 135 and sub-rule (1) of rule 20]</i>				(FOR OFFICE USE ONLY).	
				Application No:	
				Filing Date:	
				Amount of Fee Paid:	
				CBR No:	
				Signature:	
1.	APPLICANT'S REFERENCE /IDENTIFICATION NO. (AS ALLOTTED BY OFFICE)				
2.	TYPE OF APPLICATION [Please tick (✓) at the appropriate category]				
	Ordinary ()		Convention ()		PCT-NP (✓)
	Divisional ()	Patent of Addition ()	Divisional ()	Patent of Addition ()	Divisional () Patent of Addition ()
3A.	APPLICANT(S)				
	Name in Full		Nationality	Country of Residence	Address of the Applicant
	Dr. Anupam Gupta		Indian	India	3G608, AWHO Gurjinder Vihar, Greater Noida, 201310, India
3B.	CATEGORY OF APPLICANT [Please tick (✓) at the appropriate category]				
	Natural Person (✓)		Other than Natural Person		
			Small Entity ()	Start up ()	Others ()
4.	INVENTOR(S) [Please tick (✓) at the appropriate category]				
	Are all the inventor(s) same as the applicant(s) named above?		Yes (✓)		No ()
	If "No", furnish the details of the inventor(s)				
	Name	Nationality	Country of	Address of the Inventor	

			Residence			
5.	TITLE OF THE INVENTION NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF					
6.	AUTHORISED REGISTERED PATENT AGENT(S)		IN/PA No.	2786		
Name			VIVEK SINGH			
Mobile No.			+91- 9811137349			
7.	ADDRESS FOR SERVICE OF APPLICANT IN INDIA		Name	Sagacious Research Pvt. Ltd.		
Postal Address			Sagacious Research Pvt. Ltd. Plot No: B7/B8, Sector 32, Echelon Institutional Area Gurgaon, Haryana, India			
Telephone No.			+91 124 403 3431			
Mobile No.			+91 9811137349			
E-mail ID:			iprdocketing@sagaciousresearch.com vivek.singh@sagaciousresearch.com			
8.	IN CASE OF APPLICATION CLAIMING PRIORITY OF APPLICATION FILED IN CONVENTION COUNTRY, PARTICULARS OF CONVENTION APPLICATION					
	Country	Application Number	Filing Date	Name of the Applicants	Title of the Invention	IPC (as classified in the convention country)
	IN	202111025676	09-06-2021	Dr. Anupam Gupta	NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF	
9.	IN CASE OF PCT NATIONAL PHASE APPLICATION, PARTICULARS OF INTERNATIONAL APPLICATION FILED UNDER PATENT CO-OPERATION					

	TREATY (PCT)	
	International application number	International filing date
	PCT/IN2021/050722	23-06-2021
10	IN CASE OF DIVISIONAL APPLICATION FILED UNDER SECTION 16, PARTICULARS OF ORIGINAL (FIRST) APPLICATION	
	Original (first) application number	Date of filing of original (first) application
	NA	NA
11	IN CASE OF PATENT OF ADDITION FILED UNDER SECTION 54, PARTICULARS OF MAIN APPLICATION OR PATENT	
	Main application/patent Number	Date of filing of main application
	NA	NA
12	DECLARATIONS (i) Declaration by the inventor I the above named inventor is the true and first inventor for this invention and declare that the applicant herein is my assignee or legal representative (a) Date: (b) Signature: (c) Name: Dr. Anupam Gupta (ii) Declaration by the applicant(s) in the convention country (In case the applicant in India is different than the applicant in the convention country: the applicant in the convention country may sign herein below or applicant in India may upload the assignment from the applicant in the convention country or enclose the said assignment with this application for patent or send the assignment by post/electronic transmission duly authenticated within the prescribed period) I/We, the applicant(s) in the convention country declare that the applicant(s) herein is/are my/our assignee or legal representative. N/A (a) Date	

(b) Signature(s):

(c) Name(s) of the signatory:

(iii) Declaration by the applicant:

I, the applicant hereby declare that:—

☒ I am in possession of the above-mentioned invention.

☒ The complete specification relating to the invention is filed with this application.

☐ The invention as disclosed in the specification uses the biological material from India and the necessary permission from the competent authority shall be submitted by us before the grant of patent to us.

☒ There is no lawful ground of objections to the grant of the Patent to me.

☒ I am the true & first inventors.

☐ We are the assignee or legal representative of true & first inventors.

☐ The application or each of the applications, particulars of which are given in Paragraph-8, was the first application in convention country/countries in respect of our invention.

☐ We claim the priority from the above mentioned application filed in convention Country/countries and state that no application for protection in respect of the invention had been made in a convention country before that date by us or by any person from which we derive the title.

☒ Our application in India is based on international application under Patent Cooperation Treaty (PCT) as mentioned in Paragraph-9.

☐ The application is divided out of our application particulars of which are given in Paragraph -10 and pray that this application may be treated as deemed to have been filed on DD/MM/YYYY under section 16 of the act.

☐ The said invention is an improvement in or modification of the invention particulars of which are given in Paragraph -11.

13	FOLLOWING ARE THE ATTACHMENTS WITH THE APPLICATION			
	(a) Form 2			
	Item	Details	Fee (in INR)	Remarks
	Complete specification	No. of Pages: 18	1600	Including drawings
	No. of Claim(s)	No. of claims: 8 No. of Page: 3	-	-
	Abstract	No. of Page: 1	-	-
	No. of Drawing(s)	No. of Drawings: NIL No. of pages: NIL	-	-

- (b) Complete specification;
(c) Statement and undertaking on Form 3;
(d) Declaration as to inventorship on Form 5

Total fee INR 1600/- submitted online through electronic portal of Axis Bank.

I hereby declare that to the best of my knowledge, information and belief the fact and matters stated herein are correct and I request that a patent may be granted to me for the said invention.

Dated this 21st day of September,2022

Digitally signed by:
[VIVEK SINGH- IN/PA 2786]
OF SAGACIOUS RESEARCH
AGENT FOR THE APPLICANT

To
The Controller of Patents
The Patent Office at, New Delhi

Welcome Vivek Singh

[Sign out](#)

Controller General of Patents, Designs & Trade
Marks



सत्यमेव जयते

G.A.R.6
[See Rule 22(1)]
RECEIPT



Docket No 104214

Date/Time 2022/09/21 15:55:29

To
Vivek Singh

UserId: viveksingh

Sagacious Research, Plot No. B7/B8, Sector
32, Echelon Institutional Area, Gurgaon,
Haryana - 122001

CBR Detail:

Sr. No.	Ref. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Remarks
1	202217053951	TEMP/E-1/61926/2022-DEL	1600	36336	FORM 1	

TransactionID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0001026081	Online Bank Transfer	2109220019430	1600.00	1475001020000001

Total Amount : ₹ 1600.00

Amount in Words: Rupees One Thousand Six Hundred Only

Received from Vivek Singh the sum of ₹ 1600.00 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

[Print](#)[Home](#)[About Us](#)[Contact Us](#)

Electronic Acknowledgement Receipt

EFS ID:	46746947
Application Number:	17916806
International Application Number:	PCT/IN2021/050722
Confirmation Number:	4739
Title of Invention:	NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF
First Named Inventor/Applicant Name:	ANUPAM GUPTA
Customer Number:	24505
Filer:	Daniel Joshua Swirsky
Filer Authorized By:	
Attorney Docket Number:	3208-US
Receipt Date:	04-OCT-2022
Filing Date:	
Time Stamp:	04:48:57
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$ 455
RAM confirmation Number	E202204549391521
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	ApplicationDataSheet.pdf	1505105	no	6
			df9447e60e367016abedfb81dbead9f0fba64330		
Warnings:					
Information:					
2	Documents submitted with 371 (National Stage) Applications	NationalPhaseTransmittal.pdf	519195	no	4
			b824d55f7d10b6841167eea048a6bee2919d74c9		
Warnings:					
Information:					
3	Oath or Declaration filed	Declaration_signed.pdf	663090	no	1
			548174044a00e665d7a781caaa798091fc1cd710a		
Warnings:					
Information:					
4	Power of Attorney	POA_signed.pdf	878217	no	2
			e77ff6344a0c60a1a5895d4a2310d918168ad4aa		
Warnings:					
Information:					
5		3208USSpec.pdf	427485	yes	17
			90ee722afc772f1aeda9e0debc6079da603bb762		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	13	
	Claims		14	16	
	Abstract		17	17	
Page 26 of 26					

Warnings:					
Information:					
6	Certification of Micro Entity (Gross Income Basis)	Micro_Entity_Certification_signed_.pdf	673211 e8972c76c0f3d9c942574d953a9de11a1bffe0b79	no	1
Warnings:					
Information:					
7	Fee Worksheet (SB06)	fee-info.pdf	43637 82f129968d1827574c02c531dc3b90037fed1ae6	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			4709940		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		Attorney Docket No. 3208-US
		U.S. Application No. (if known, see 37 CFR 1.5)
International Application No. PCT/IN2021/050722	International Filing Date JULY 23, 2021	Priority Date Claimed JUNE 9, 2021
Title of Invention NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF		
First Named Inventor Anupam GUPTA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information. 1. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). NOTE: The express request under 35 U.S.C. 371(f) will not be effective unless the requirements under 35 U.S.C. 371(c)(1), (2), and (4) for payment of the basic national fee, copy of the International Application and English translation thereof (if required), and the oath or declaration of the inventor(s) have been received. 2. ☐ A copy of the International Application (35 U.S.C. 371(c)(2)) is attached hereto (not required if the International Application was previously communicated by the International Bureau or was filed in the United States Receiving Office (RO/US)). 3. An English language translation of the International Application (35 U.S.C. 371(c)(2)) a. ☐ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4). 4. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) a. ☒ is attached. b. ☐ was previously filed in the international phase under PCT Rule 4.17(iv). Items 5 to 8 below concern amendments made in the international phase. <u>PCT Article 19 and 34 amendments</u> 5. ☐ Amendments to the claims under PCT Article 19 are attached (not required if communicated by the International Bureau) (35 U.S.C. 371(c)(3)). 6. ☐ English translation of the PCT Article 19 amendment is attached (35 U.S.C. 371(c)(3)). 7. ☐ English translation of annexes (Article 19 and/or 34 amendments only) of the International Preliminary Examination Report is attached (35 U.S.C. 371(c)(5)). <u>Cancellation of amendments made in the international phase</u> 8a. ☐ Do not enter the amendment made in the international phase under PCT Article 19. 8b. ☐ Do not enter the amendment made in the international phase under PCT Article 34. NOTE: A proper amendment made in English under Article 19 or 34 will be entered in the U.S. national phase application absent a clear instruction from applicant not to enter the amendment(s). The following items 9 to 17 concern a document(s) or information included. 9. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 10. ☐ A preliminary amendment. 11. ☒ An Application Data Sheet under 37 CFR 1.76. 12. ☐ A substitute specification. NOTE: A substitute specification cannot include claims. See 37 CFR 1.125(b). 13. ☒ A power of attorney and/or change of address letter. 14. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.3 and 37 CFR 1.821-1.825 (not required if sequence listing in text format was indicated on the PCT Request as part of the International Application and the sequence listing was published as part of the international application). 15. ☐ Assignment papers (<i>cover sheet and document(s)</i>). Name of Assignee: _____ 16. ☐ 37 CFR 3.73(c) Statement (<i>when there is an Assignee</i>). _____		

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLN. No. (if known – see 37 CFR 1.5)	INTERNATIONAL APPLICATION No. PCT/IN2021/050722	ATTORNEY DOCKET No. 3208-US
17. ☐ Other items or information:		
The following fees have been submitted.		CALCULATIONS
18. ☒ Basic national fee (37 CFR 1.492(a))		\$320
19. ☒ Examination fee (37 CFR 1.492(c))		\$ 800
• If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0 • All other situations		\$800
20. ☒ Search fee (37 CFR 1.492(b))		\$ 700
• If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0 • Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority • International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... \$540 • All other situations		\$700
TOTAL OF 18, 19, and 20 =		\$ 1820
☐ Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) in an electronic medium or computer program listing in an electronic medium) (37 CFR 1.492(j)). Fee for each additional 50 sheets of paper or fraction thereof \$420		\$
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)
- 100 =	/ 50 =	x \$420
Surcharge for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).....		\$160
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	- 20 =	x \$100
Independent claims	- 3 =	x \$480
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$860
Fee for submission of Sequence Listing text file of 300 MB to 800 MB (37 CFR 1.21(o)(1)).....		\$1,060
Fee for submission of Sequence Listing text file of more than 800 MB (37 CFR 1.21(o)(2)).....		\$10,500
Processing fee for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).....		\$140 +
TOTAL OF ABOVE CALCULATIONS =		\$ 1820
☒ Applicant asserts small entity status. See 37 CFR 1.27. Fees above are reduced by ½.		
☒ Applicant certifies micro entity status. See 37 CFR 1.29. Fees above are reduced by ¾. Applicant must attach form PTO/SB/15A or B or equivalent.		
TOTAL NATIONAL FEE =		\$ 455
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).....		\$50.00 per property +
TOTAL FEES ENCLOSED =		\$ 455

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 501380 in the amount of \$ 455 to cover the above fees.
- c. ☐ The Director is hereby authorized to charge additional fees which may be required, or credit any overpayment, to Deposit Account No. _____ as follows:
- i. ☐ any required fee.
- ii. ☐ any required fee except for excess claims fees required under 37 CFR 1.492(d) and (e) and multiple dependent claim fee required under 37 CFR 1.492(f).
- d. ☒ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. The PTO-2038 should only be mailed or faxed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO.

ADVISORY: If filing by EFS-Web, do **NOT** attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be advised that this is **not** recommended and by doing so your **credit card information may be displayed via PAIR**. To protect your information, it is recommended to pay fees online by using the electronic payment method.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

- ☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013, and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.

NOTE 1: By providing this statement under 37 CFR 1.55 or 1.78, **this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.**

NOTE 2: A U.S. national stage application may not claim priority to the international application of which it is the national phase. The filing date of a U.S. national stage application is the international filing date. See 35 U.S.C. 363.

Correspondence Address

- ☒ The address associated with Customer Number: 24505 OR ☐ Correspondence address below

Name					
Address					
City		State		Zip Code	
Country				Telephone	
Email					

Signature	/Daniel J. Swirsky Reg. No. 45,148/	Date	OCTOBER 4, 2022
Name (Print/Type)	Daniel J. Swirsky	Registration No. (Attorney/Agent)	45,148

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Acknowledgement Receipt

The USPTO has received your submission at **04:48:57** Eastern Time on **04-OCT-2022** .

\$ **455** fee paid by e-Filer via RAM with Confirmation Number: E202204549391521.

eFiled Application Information

EFS ID	46746947
Application Number	17916806
International Application Number	PCT/IN2021/050722
Confirmation Number	4739
Title	NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF
First Named Inventor	ANUPAM GUPTA
Customer Number or Correspondence Address	24505
Filed By	Daniel Joshua Swirsky
Attorney Docket Number	3208-US
Filing Date	
Receipt Date	04-OCT-2022
Application Type	U.S. National Stage under 35 USC 371

Application Details

Sequence	Submitted Files	Page Count	Document Description	File Size	Warnings
1	ApplicationDataSheet.pdf	6	Application Data Sheet	1505105 bytes	 PASS
No validation errors found.					
2	NationalPhaseTransmittal.pdf	4	Documents submitted with 371 (National Stage) Applications	519195 bytes	 PASS
No validation errors found.					
3	Declaration_signed.pdf	1	Oath or Declaration filed	663090 bytes	 PASS
No validation errors found.					
4	POA_signed.pdf	2	Power of Attorney	878217 bytes	 PASS
No validation errors found.					
5	3208USSpec.pdf	17		427485 bytes	 PASS
No validation errors found.					
	Document Description	Page Start	Page End		
	Specification	1	13		
	Claims	14	16		
	Abstract	17	17		
6	Micro_Entity_Certification_signed_.pdf	1	Certification of Micro Entity (Gross Income Basis)	673211 bytes	 PASS
No validation errors found.					

No validation errors found.

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

If you need help:

- *To ask questions about Patent e-Filing, or to suggest improvements to the online system, or report technical problems, please call the Patent Electronic Business Center at (866) 217-9197 (toll free) or send email to EBC@uspto.gov.*
- *Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).*
- *For general questions regarding a petition, or requirements for filing a petition, contact the Office of Petitions Help Desk at 1 800-786-9199.*



Government
of Canada

Gouvernement
du Canada

[Home](#) → [Business](#) → [Intellectual property and copyright](#) → [Patents](#)
→ [General Correspondence](#) → Transaction Confirmation

Signed in as epadre16

[Access my profile](#)

[Sign out](#)

Electronic Transaction Confirmation

Your transaction was successfully processed.

Please print and/or save a copy for your records.

Transaction Information

Confirmation Number: pgc_epadre16_20221212092556322_15066512

Status: Success

Date: December 12, 2022 9:25:56 AM

Amount: \$50.00

Please DO NOT send the same application by facsimile, mail or email.

[Print](#)

[Patent General Correspondence](#)

Version number:

4.0.7



Government
of Canada

Gouvernement
du Canada

[Home](#) → [Business](#) → [Intellectual property and copyright](#) → [Patents](#)
→ [General Correspondence](#) → Transaction Confirmation

Signed in as epadre16

 [Access my profile](#)

 [Sign out](#)

Electronic Transaction Confirmation

✔ Your transaction was successfully processed.

i Please print and/or save a copy for your records.

Transaction Information

Confirmation Number: pgc_epadre16_20221212092556322_15066512

Status: Success

Date: December 12, 2022 9:25:56 AM

Amount: \$50.00

i Please DO NOT send the same application by facsimile, mail or email.

[Print](#)

[Patent General Correspondence](#)

Version number:

4.0.7



Government
of Canada

Gouvernement
du Canada

[Home](#) → [Business](#) → [Intellectual property and copyright](#) → [Patents](#)
→ [General Correspondence](#) → Preview

Signed in as epadre16

[Access my profile](#)

[Sign out](#)

Preview

i To save, select **File, Save As** from your browser menu. Then "Save as type: Webpage, HTML only (*.htm;*.html)". Attachments cannot be imported when loading a general correspondence.

i Attention!

By clicking "Submit", you will finish your payment process and you will be no longer able to modify the form. Please print and/or save a copy for your records.

If you need to modify the form inputs, click the "Back to form" button now.

⚠ Temporary Confirmation Number: pgc_epadre16_20221212092556322

Your submission is not completed until you receive an Electronic Transaction Confirmation receipt.

When applicable, an Order ID will be provided in the next steps which will be added to the Temporary number provided above and will be shown on your Electronic Transaction Confirmation receipt as your final Confirmation Number.

Please proceed to the next steps by clicking "Submit" below.

GENERAL CORRESPONDENCE (PATENTS)

DATE: December 12, 2022 9:25:56 AM

Application

Application or Patent Number: PCT/IN2021/050722

Title: NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF

Applicant or Inventor Name: GUPTA, Anupam

Contact Name

Last Name: Sabeta

First Name: Anton

Initial: C.

Name/Firm: Aird & McBurney LP

Complete Address

Address Line 1: 1800-181 Bay St

City: Toronto

Province/State: Ontario

Country: Canada

Postal/Zip Code: M5J 2T9

Telephone Number: 14168631500

Fax Number:

Email Address: patentmail@airdmcburney.com

Client Reference No.: 16582-9 (304720) ACS

Communicate by: Electronic Mail (Non secure)

Comments

2023 Maintenance Fee Request for Canadian Patent Application No. b/o
PCT/IN2021/050722

Fees (small entity fee)

Fee Description	Amount
Application Maintenance Fee - 2nd anniversary, small entity fee (1 x \$50.00)	\$50.00
Total	\$50.00

Attachments

File: 2023 Maintenance Fee Letter - December 12_ 2022 - 16582-9 ACS.pdf

Comments:

Type of Document: Other

 Back to form

Print

Submit

Version number:
4.0.7



Government
of Canada

Gouvernement
du Canada

[Home](#) → [Business](#) → [Intellectual property and copyright](#) → [Patents](#)

→ [General Correspondence](#) → Preview

Signed in as epadre16

[Access my profile](#)

[Sign out](#)

Preview

i To save, select **File, Save As** from your browser menu. Then "Save as type: Webpage, HTML only (*.htm;*.html)". Attachments cannot be imported when loading a general correspondence.

i Attention!

By clicking "Submit", you will finish your payment process and you will be no longer able to modify the form. Please print and/or save a copy for your records.

If you need to modify the form inputs, click the "Back to form" button now.

⚠ Temporary Confirmation Number: pgc_epadre16_20221212092556322

Your submission is not completed until you receive an Electronic Transaction Confirmation receipt.

When applicable, an Order ID will be provided in the next steps which will be added to the Temporary number provided above and will be shown on your Electronic Transaction Confirmation receipt as your final Confirmation Number.

Please proceed to the next steps by clicking "Submit" below.

GENERAL CORRESPONDENCE (PATENTS)

DATE: December 12, 2022 9:25:56 AM

Application

Application or Patent Number: PCT/IN2021/050722

Title: NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF

Applicant or Inventor Name: GUPTA, Anupam

Contact Name

Last Name: Sabeta

First Name: Anton

Initial: C.

Name/Firm: Aird & McBurney LP

Complete Address

Address Line 1: 1800-181 Bay St

City: Toronto

Province/State: Ontario

Country: Canada

Postal/Zip Code: M5J 2T9

Telephone Number: 14168631500

Fax Number:

Email Address: patentmail@airdmcburney.com

Client Reference No.: 16582-9 (304720) ACS

Communicate by: Electronic Mail (Non secure)

Comments

2023 Maintenance Fee Request for Canadian Patent Application No. b/o
PCT/IN2021/050722

Fees (small entity fee)

Fee Description	Amount
Application Maintenance Fee - 2nd anniversary, small entity fee (1 x \$50.00)	\$50.00
Total	\$50.00

Attachments

File: 2023 Maintenance Fee Letter - December 12_ 2022 - 16582-9 ACS.pdf

Comments:

Type of Document: Other

 Back to form

Print

Submit

Version number:
4.0.7



Courtoisie - Lettre confirmant l'entrée en phase nationale en vertu du PCT Courtesy - Letter Acknowledging PCT National Phase Entry

AIRD & MCBURNEY LP
patentmail@airdmcburney.com



Détails de la lettre Letter Details

Date de la lettre: Letter Date:	2023/01/18
N° de la demande: Application N°:	3,183,246
Votre n° de référence: Your Reference N°:	16582-9 ACS
Date de dépôt: Filing Date:	2021/07/23

Date d'entrée en phase nationale: National Phase Entry Date:	2022/11/30
N° de la demande PCT /: PCT Application N°:	PCT/IN 2021/050722
Demandeur(s)/Applicant(s):	GUPTA, ANUPAM
Inventeur(s)/Inventor(s):	GUPTA, ANUPAM
Titre de l'invention: Title of invention:	NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF
Données de priorité/Priority Data:	IN (202111025676) 2021/06/09

Les dossiers du Bureau des brevets indiquent que le demandeur s'est conformé aux exigences applicables pour l'entrée en phase nationale en vertu du PCT au Canada au titre de l'art. 154 des *Règles sur les brevets*.

Patent Office records indicate that the applicant has complied with the applicable requirements to enter the PCT national phase in Canada under s.154 of the *Patent Rules*.

Vous devez payer une taxe annuelle pour maintenir en état votre demande de brevet pour chaque période d'une année à compter du deuxième anniversaire de la date de dépôt de votre demande.

Annual fees to maintain your patent application are required for each one-year period from the second anniversary of the filing date of the application.

Une demande de brevet ne sera examinée que sur demande.

A patent application will only be examined on request.

Pour de plus amples renseignements concernant cette lettre, ou pour des renseignements relatifs aux paiements des taxes pour le maintien en état, veuillez consulter le *Recueil des pratiques du Bureau des brevets* (RPBB) sur le site canada.ca/brevets ou téléphoner au 1 819 953-7683.

For more information regarding this letter, or information relating to maintenance fee payments, please refer to the *Manual of Patent Office Practice* (MOPOP) at canada.ca/patents or phone 1-819-953-7683.

Acknowledgement of receipt

We hereby acknowledge receipt of the form for entry into the European phase (EPO as designated or elected Office) as follows:

Submission number	11596756	
PCT application number	PCT/IN2021/050722	
EP application number	21944964.2	
Date of receipt	19 December 2022	
Receiving Office	European Patent Office, The Hague	
Your reference	P10190PCEP	
Applicant		
Country		
Documents submitted	package-data.xml application-body.xml	ep-euro-pct.xml epf1200.pdf (4 p.)
Submitted by	CN=Mark Rolinec 47334	
Method of submission	Online	
Date and time receipt generated	19 December 2022, 13:47 (CET)	
Message Digest	20:2B:BD:27:25:AA:A0:C7:AD:C4:07:D5:18:EA:E9:89:17:1E:67:E9	

/European Patent Office/

replaces the originally filed claims unless replaced by the amendments attached. Comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are attached. <i>Where necessary, further details should be attached as "Other documents"</i>	☐ ☐
6.2 Proceedings before the EPO as elected Office (PCT II) are to be based on the following documents: the documents on which the international preliminary examination report is based, including any annexes unless replaced by the amendments attached. comments on the international preliminary examination report established by the EPO as the International Preliminary Examining Authority and/or observations are enclosed. <i>Where necessary, further details should be attached as "Other documents"</i> If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.	☐ ☐ ☐ ☐
6.3 A copy of the results of the search carried out by the authority with which the previous application(s) whose priority is claimed was (were) filed is attached (R. 141(1) EPC).	☐
7. Translations Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below: <i>* In proceedings before the EPO as designated or elected Office (PCT I + II):</i> 7.1 Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material 7.2 Translation of the priority application(s) (to be filed only at the EPO's request, Rule 53(3) EPC) 7.3 It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 53(3) EPC) <i>* In addition, in proceedings before the EPO as designated Office (PCT I):</i> 7.4 Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6). <i>* In addition, in proceedings before the EPO as elected Office (PCT II):</i> 7.5 Translation of any annexes to the international preliminary examination report	☐ ☐ ☐ ☐ ☐ ☐ ☐
8. Biological material The invention uses and/or relates to biological material deposited under Rule 31 EPC. The particulars referred to in Rule 31(1)(c) EPC (if not yet known, the depositary institution and the identification reference(s)) [number, symbols, etc.] of the depositor are given in the international publication or in the translation submitted in Section 7 on: page(s) / line(s) The receipt(s) of deposit issued by the depositary institution is (are) enclosed. will be filed later. Waiver of the right to an undertaking from the requester pursuant to Rule 33(2) EPC attached.	☐ ☐ ☐ ☐ ☐
9. Nucleotide and amino acid sequences The international application discloses nucleotide and/or amino acid sequences. 9.1 The sequence listing was filed under Rule 5.2(a) PCT, or furnished to the EPO as ISA under Rule 13ter. 1(a) PCT, or is otherwise available to the EPO, in a computer-readable format complying with the WIPO Standard applicable at the international date of filing. 9.2	☐ ☐

The sequence listing is attached in a computer-readable format complying with the WIPO Standard applicable at the international date of filing (Rule 163(3) EPC).		☐	
The sequence listing does not include matter which goes beyond the content of the application as filed.		☐	
10. Designation of contracting states All the contracting states party to the EPC at the time of filing of the international patent application and designated in the international application are deemed to be designated (see Article 79(1) EPC).			☒
11. Extension/Validation This application is deemed to be a request to extend the effects of the European patent application and the European patent granted in respect of it to all non-contracting states to the EPC designated in the international application with which extension or validation agreements were in force on the date on which the application was filed. However, the request is deemed withdrawn if the extension fee or the validation fee, whichever is applicable, is not paid within the prescribed time limit. 11.1 It is intended to pay the extension fee(s) for the following state(s): 11.2 It is intended to pay the validation fee(s) for the following state(s): Note: Under the automatic debiting procedure, extension and/or validation fees will be debited only for states indicated here unless the EPO is instructed otherwise before expiry of the period for payment.			☐
12. Acceleration of procedure 12.1 Early processing Early processing of the application pursuant to Article 23(2) / 40(2) PCT is hereby requested ("early entry into the European phase") 12.2 Waivers The applicant waives his right to the communication under Rules 161(1) or (2) and 162 EPC. The applicant waives his right to be asked under Rule 70(2) EPC whether he wishes to proceed further with the application.			☐ ☐ ☐
13. List of enclosed documents			
	Description of document	Original file name	Assigned file name
14. Method of payment: Automatic debit order Currency The European Patent Office is hereby authorised, under the Arrangements for the automatic debiting procedure, to debit from the deposit account indicated any fees and costs falling due. Deposit account number Account holder			☒ EUR 28003226 LeoBlu Patentanwälte Rolinec Winter PartG mbB
15. Any refunds should be made to the following EPO deposit account: Number and account holder			☒ LeoBlu Patentanwälte Rolinec Winter PartG mbB, 28003226
16. Fees			
17. Annotations			
18. Signature(s) of applicant(s) or representative Place: München Date: 19 December 2022 Signed by: Mark Rolinec 47334 Representative name: Mark Rolinec Capacity: (Representative)			

Table for section 6 of Form 1200.3

In accordance with the Notice from the European Patent Office dated 26 January 2009 concerning the 2009 fee structure (OJ EPO 2009, 118, and Guidelines for Examination in the EPO, April 2009, A-III, 13.2), the amount of the additional fee (Art. 2, item 1a, Rules relating to Fees) for the pages of this European patent application is calculated as follows:

Documents intended for proceedings before the EPO (R. 159 (1) (b) EPC) and for calculating the additional fee (Art. 2, item 1a, RFees):

	Page(s) from ... to ...	Number of pages
Description: International application as published	1 to 13	13
Claims: International application as published	14 to 16	2
Drawings: NONE	-	-
Abstract: Default count: one page		1
Total number of pages		16
Fee-exempt pages (Art. 2, item 1a, RFees)		-35
Number of pages to be paid for		0
		(x 16 EUR per page)
Total amount payable	EUR	0



Official Receipt

Your submission has been successfully received.

This is your official filing receipt - you can save or print this page to retain it for your personal records now, or view it later in your filing history.

Submission details

Reference Number **AMCZ-2311906757**
Submission Time 27/01/2023 04:48 PM
Submitter User ID mail.laminarip.com

Transaction reference	Description	Fee amount
APSZ-2311906742	Your reference: P113196	
	Patent 2021449881	
	Patents new application (national phase entry)	\$370.00
Payment total		\$370.00

Note: Amounts include GST where applicable. Under division 81 of A New Tax System (Goods and Services Tax) Act 1999, GST is not payable on the purchase of any statutory items from IP Australia.



8 February 2023



Delivering a world leading IP system

Phone: 1300 651 010
International: +61 2 6283 2999

www.ipaustralia.gov.au

ABN: 38 113 072 755

National phase entry for patent application

LAMINAR IP PTY LTD
PO Box 599
Milsons Point NSW 1565
Australia

Your reference	P113196
Application number	2021449881
Applicant name	Anupam Gupta

Dear LAMINAR IP PTY LTD,

We have received your request for national phase entry for PCT application number PCT/IN2021/050722 and it has entered the national phase. The filing date is 23 July 2021 and the national phase entry date is 27 January 2023.

Please review the details on the attached application summary to ensure they are correct.

Details of this patent application can be viewed on [AusPat](#), our Australian patent search database.

Yours sincerely,

IP Australia

Application summary

Standard patent application details

Application number: 2021449881
Title: Non-steroidal topical composition and method thereof
Your reference: P113196

Documents filed

The specification on file contains the following documents:

- Description
- Claim(s)

This application currently has an abstract on file.

Applicant and inventor details

Applicant name(s) and address(es) *(as it will appear on certificate/s)* :

Anupam Gupta of 3G608, AWHO Gurjinder Vihar, Greater Noida 201310 India

Inventor name(s): GUPTA, Anupam

Agent details

Agent Name LAMINAR IP PTY LTD
Address for correspondence: PO Box 599
Milsons Point NSW 1565
Australia
Address for legal service: PO Box 599
Milsons Point NSW 1565
Australia

Priority details

Number	Date	Country
202111025676	9 June 2021	IN

Relevant dates

Filing date: 23 July 2021
National phase entry date: 27 January 2023
Continuation fee due: 23 July 2025
Date of patent: 23 July 2021
Expiry date: 23 July 2041

Case Details Report

Date and Time: 27 Jan 2023 07:13:40 p.m.

www.iponz.govt.nz

INTERNATIONAL: +64 3 962 2607

NATIONAL: 0508 4 IPONZ

(0508 447 669)

Patent Number (11): 796740

Client Reference: P113196NZ

Status: Filed

Application type: National Entry PCT

Technology group: Chemical

Next Maintenance Due Date: 23 Jul 2025

National Phase Entry Date: 27 Jan 2023

Submitted Date: 27 Jan 2023

Filing Date (22): 23 Jul 2021

Expiry Date: 23 Jul 2041

Maintenance Date: 23 Jul 2025

Expedited Examination Requested: No

Examination Requested: No

GPPH Requested: No

Under Proceeding: No

OPI Date: 15 Dec 2022

Complete Specification Filing Date: 23 Jul 2021

PCT Publication Number: WO/2022/259260

Application made under: Patents Act 2013

Granted as Patent of addition: No

PCT Application

Number:

PCT/IN2021/050722

Patent Title: NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF

Maori Conflict possible: No

Traditional knowledge: No

Abstract:

[Redacted Abstract Content]

Patent Specifications:

Title	Filing Date	Publication Date	Status
NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF	27 Jan 2023		Proposed

International Patent Classification (51): A61K 36/9066, A61K 36/31, C11D 3/04

Convention Priority:

Country	Priority Date	Priority Number	Retrieved from WIPO DAS
India	09 Jun 2021	202111025676	

GUPTA, Anupam	Physical : 3G608, AWHO Gurjinder Vihar, Greater Noida 201310, , IN
---------------	--

Agent:

Laminar IP Pty Ltd	Postal: PO BOX 599, NSW, Milsons Point 1565, AU Physical: Level 13, 111 Elizabeth St, NSW, Sydney 2000, AU Service: PO BOX 599, NSW, Milsons Point 1565, AU Email Address: mail@laminarip.com
--------------------	--

Applicant(s):

GUPTA, Anupam	Physical: 3G608, AWHO Gurjinder Vihar, Greater Noida 201310, , IN
---------------	---

Contact Details: Laminar IP Pty Ltd, PO BOX 599, NSW, Milsons Point 1565, AU

Linked Cases: None

This search facility provides information from the intellectual property registers administered and maintained by IPONZ. Whilst IPONZ takes all reasonable care in the provision of its services, IPONZ and the Ministry of Business, Innovation & Employment do not accept any responsibility or liability for any action taken in reliance on this information or for any error, inadequacy, deficiency or flaw in or omission from the information provided. This site is not intended to be a comprehensive or complete source of intellectual property information. To obtain further assistance on the use of this Internet site please contact us.

整理番号:IP230015 PCT/IN2021/050722 (Proof) 提出日:令和 5年 1月26日 1/E

【書類名】 国内書面
【整理番号】 IP230015
【あて先】 特許庁長官殿
【出願の表示】
【国際出願番号】 PCT/IN2021/050722
【出願の区分】 特許
【発明者】
【住所又は居所】 インド国, 201310 グレーター ノイダ, ヴィハール, エーダブリュエイチオー グルジンダー, 3ジー608
【氏名】 グプタ, アヌパン
【特許出願人】
【住所又は居所】 インド国, 201310 グレーター ノイダ, ヴィハール, エーダブリュエイチオー グルジンダー, 3ジー608
【住所又は居所原語表記】 3G608, AWHO Gurjinder, Vihar, Greater Noida 201310 (IN)
【氏名又は名称】 グプタ, アヌパン
【氏名又は名称原語表記】 GUPTA, Anupam
【代理人】
【識別番号】 110003487
【氏名又は名称】 弁理士法人東海特許事務所
【代表者】 安達 友和
【電話番号】 052-265-6025
【手数料の表示】
【指定立替納付】
【納付金額】 14,000円

受領書

令和 5年 1月26日
特許庁長官

識別番号 110003487
氏名(名称) 弁理士法人東海特許事務所 様

以下の書類を受領しました。

項番	書類名	整理番号	受付番号	提出日	出願番号通知(事件の表示)	アクセスコード
1	国内書面	IP230015	52300165564	令 5. 1. 26	PCT/IN2021/ 50722	以 上

REPUBLIC OF SOUTH AFRICA
PATENTS ACT, 1978
**ENTRY OF INTERNATIONAL APPLICATION
UNDER THE PATENT COOPERATION TREATY
INTO SOUTH AFRICAN NATIONAL PHASE
AND ACKNOWLEDGMENT OF RECEIPT**

(Section 42E(1) - Regulation 67B)

The processing under the Patents Act, 1978 of the undermentioned international application designating South Africa is hereby requested on the basis of this form.

Official Application No.		Applicant's or Agent's Reference
21	01	GPN00006127ZA
2023/01091		

International Application No.	International filing Date	Priority Date
PCT/IN2021/050722	2021/07/23	2021/06/09
71 Full Name(s) of Applicant(s)		
GUPTA, Anupam 3G608 , AWHO Gurjinder, Vihar, Greater Noida, 201310, India		

54	Title of invention
NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF	

The applicant has claimed priority (if any) as set out in the abovementioned international application
--

This application is for a patent of addition to patent application No.		
21	01	

The abovementioned international application was filed in English or has been published under the Patent Cooperation Treaty in English	YES	X	NO	
--	-----	---	----	--

This application is accompanied by:	
-------------------------------------	--

	1.	Translation of the international application
	2.	Certified priority document(s)
	3.	Translation(s) of the priority document(s)
X	4.	A copy of the Form P2 (particulars for the register)
X	5.	A declaration and power of attorney on Form P3
X	6.	Statement on the use of indigenous biological resource, genetic resource traditional knowledge or use on Form P26
X	7.	Publication particulars and abstract (Form P.8)
X	8.	

74	Address of Service:
Sibanda and Zantwijk Oaktree Corner, 9 Kruger Street, Oaklands (PO Box 1615 Houghton 2041), Johannesburg, 2192 SOUTH AFRICA	

Dated this 25th day of January 2023

Digitally signed by : Dirk Antonie Van Zantwijk

.....
Signature of Applicant(s)

This is returned to the applicant's
address for service as proof of lodging.

RECEIVED
Official Date Stamp
..... Registrar of Patents

This document has been generated by CIPC on this 26th day of January 2023

REPUBLIC OF SOUTH AFRICA

REGISTER OF PATENTS

PATENTS ACT, 1978

Official application No.			Lodging date: Provisional			Acceptance date		
21	01	2023/01091	22			47		
International classification			Lodging date: National Phase			Granted date		
51	A61K;C11D		23	2023/01/25				
International Application No.			International filling Date			Priority Date		
PCT/IN2021/050722			2021/07/23			2021/06/09		
71	Full name(s) of applicant(s)/Patentee(s):							
GUPTA, Anupam								
71	Applicant substituted:					Date registered		
71	Assignee(s):					Date registered		
72	Full name(s) of inventor(s):							
GUPTA, Anupam								
Priority claimed:			Country		Number		Date	
			33 IN		31 202111025676		32 2021/06/09	
54	Title of invention							
NON-STEROIDAL TOPICAL COMPOSITION AND METHOD THEREOF								
Address of applicant(s)/patentee(s):								
3G608 , AWHO Gurjinder, Vihar, Greater Noida, 201310 INDIA								
74	Address for service							
Sibanda and Zantwijk Oaktree Corner, 9 Kruger Street, Oaklands (PO Box 1615 Houghton 2041), Johannesburg, 2192 SOUTH AFRICA Reference No. GPN00006127ZA								
61	Patent of addition No.				Date of any change			
Fresh application based on.				Date of any change				

REPUBLIC OF SOUTH AFRICA
PATENTS ACT, 1978
APPLICATION OR REQUEST TO THE REGISTRAR
(REGULATION 39)

OFFICIAL APPLICATION NO.		
21	01	2023/01091

AGENT REFERENCE
GPN00006127ZA

IN THE NAME OF:	
71	GUPTA, Anupam

In terms of the following section(s) 42 of the Act and/or regulation(s) 39, 44 of the Patent Regulations, the applicant hereby request the following: Request for expedited acceptance in terms of section 42, regulation 39 and 44.
--

Documents, if any, lodged in support of the request:
N/A

ADDRESS FOR SERVICE	
74	Sibanda and Zantwijk Oaktree Corner, 9 Kruger Street, Oaklands (PO Box 1615 Houghton 2041), Johannesburg, 2192 SOUTH AFRICA

25 January 2023

Digitally signed by : Dirk Antonie Van
Zantwijk

Signature of Applicant

FOR OFFICIAL USE ONLY

The above application or request is hereby allowed/refused.

Reasons for refusal of conditions of allowance, if any:

OFFICIAL DATE STAMP
_____ REGISTRAR OF PATENTS

Duplicate
Sales Journal

POSTAL ADDRESS

P.O. Box 429
PRETORIA
0001

PHYSICAL ADDRESS

THE DTI Campus (Block F-Entfufukweni)
77 Meintjies Street
SUNNYSIDE
PRETORIA
0001

CALL CENTER

0861 843 384 (South Africa)
+27 11 254 9405 (International)

Sales Journal Number : 73690010
Date : 2023/01/26

Debit Code SZLAW1
Agent PAULO MIGUEL PEREIRA LOPES
Postal Address PO BOX 1615 HOUGHTON
JOHANNESBURG GAUTENG 2041
SOUTH AFRICA

Document Reference P233896782
File Reference 2023\01091

Form Code Application for a patent accompanied by a complete
specification in terms of section 30(1) {reg. 22(1)(a) and
(e)}

Debit Amount -R590

FOR OFFICE USE ONLY

Duplicate Sales Journal

Sales Journal Number : 73690010 **Date :** 2023/01/26

Debit Code SZLAW1
Agent PAULO MIGUEL PEREIRA LOPES
Postal Address PO BOX 1615 HOUGHTON
JOHANNESBURG GAUTENG 2041
SOUTH AFRICA

Document Reference P233896782
File Reference 2023\01091

Form Code Application for a patent accompanied by a complete
specification in terms of section 30(1) {reg. 22(1)(a) and
(e)}

Debit Amount -R590

Duplicate
Sales Journal

POSTAL ADDRESS

P.O. Box 429
PRETORIA
0001

PHYSICAL ADDRESS

THE DTI Campus (Block F-Entfutukweni)
77 Meintjies Street
SUNNYSIDE
PRETORIA
0001

CALL CENTER

0861 843 384 (South Africa)
+27 11 254 9405 (International)

Sales Journal Number : 73690011
Date : 2023/01/26

Debit Code SZLAW1
Agent PAULO MIGUEL PEREIRA LOPES
Postal Address PO BOX 1615 HOUGHTON
JOHANNESBURG GAUTENG 2041
SOUTH AFRICA

Document Reference P233896783
File Reference 2023\01091

Form Code r) Any other request not provided for

Debit Amount -R50

FOR OFFICE USE ONLY

Duplicate Sales Journal

Sales Journal Number : 73690011

Date : 2023/01/26

Debit Code SZLAW1
Agent PAULO MIGUEL PEREIRA LOPES
Postal Address PO BOX 1615 HOUGHTON
JOHANNESBURG GAUTENG 2041
SOUTH AFRICA

Document Reference P233896783
File Reference 2023\01091

Form Code r) Any other request not provided for

Debit Amount -R50

Date: 16 December 2022

To,
Dr. Anupam Gupta
Anupam Herbals
Jogipura, Near Lavela chowk, Budaun
2436601

Sub: End to End Clinical Trial

Anupam herbals and partners (www.anupamherbalsindia.com) desires that its research product, AH-OSTEOCARE (www.ah-Osteocare.in) with International Application Number PCT/IN2021/050722 is required to be studied by way of human clinical trial (Phase 3) as per drugs and cosmetics act in India, as per Schedule-Y, Indian GCP, ICH- GCP or any applicable good clinical practice guidelines. Hence Anupam Lifescience Pvt. Ltd. (www.anupamlifesciences.in), the Sponsor has been searching for good clinical trial and Dr Anupam Gupta approach to Syncorp Health Pvt. Ltd. for the conduct of human clinical trial.

Syncorp Health Pvt. Ltd would be the CRO partner and committed to conduct the clinical trial after obtaining of the IRB approval and CTIRI registration as per the need of law of the land. Syncorp Health Pvt. Ltd would take approximately 3.5 months of time starting from Protocol development to providing of the final signed Clinical Study Report (CSR) to Dr Anupam Gupta.

Thanking You,

For **SYNCORP HEALTH PRIVATE LIMITED**


Subham Dutta
Director
Director

SYNCORP HEALTH PVT. LTD.

Building # 06, 3rd floor, 2nd Main Road, Sarvobhogam Nagar, Arekere, Bengaluru, Karnataka 560076

Ph. No. 08049774772 | E-mail: info@syncorp.in | www.syncorphealth.com

GSTIN: 29ABBCS3851N1ZT | CIN: U73100KA2019PTC120119



"MARKETING ONLY INNOVATIVE PRODUCTS"

ANUPAM LIFE SCIENCES Pvt. Ltd.

Providing healthcare globally through innovation and bringing niche products to the market

ALS * +91-7505441858 * info@anupamlifesciences.com * www.anupamlifesciences.in



NEW PRODUCT LAUNCH

Executive Summary

THE PROBLEM

Majority of our current patients have expressed the need for a new painkiller which is free of side-effects, does not cause stomach aches (due to acidity), and is applicable to patients who have Kidney problems or are on dialysis.


To better serve our patients and to branch into a new market, the Research House has developed a new topical painkiller ointment which is a part of alternative medicine, is free of side-effects, is long acting on local application, is a substitute to the need of oral painkillers, and is effective even when other, oral or local, painkillers fail to provide the desired relief.

THE SOLUTION

This new research product is far superior when compared to the existing painkillers. The relief lasts for at least 6 to 8 hours and can last longer upon multiple applications. For application, a small quantity must be applied at the affected area.

For OsteoArthritis of knee joint: The feedback of its local application has been extraordinary. It provides a delayed operative intervention, is effective even when used with other painkillers, and decreases the need of oral painkillers while the patients go about their day-to-day activities.

For kidney patients: This new invention provides immense relief in knee and other musculoskeletal pain for a long duration without the need of oral painkillers and without any side effects on the kidney.



ALS * +91-7505441858 * info@anupamlifesciences.in * www.anupamlifesciences.in



NEW PRODUCT LAUNCH

Executive Summary

THE VALUE

The new qualities of osteoarthritic and renal segments will not only appeal to the existing target market, but also to the new markets where our brand has received a much higher acceptance by the patients. The new qualities make the product non-competitive, natural, without side-effects, and uniquely featured in the OA of knee and nephrology segment Which is unique in 7.8 billion dollars global market.

This product has a patent filed in 146 countries and separately in India/USA/Canada/Australia/NZ/European-union/Japan/South Africa.

PURPOSE OF VISIT

1. We Started Pan India association with heilenbiopharm (www.heilenbiopharm.com) for marketing and searching similar joint ventures worldwide for global marketing Association through marketing office at Canada.
2. We are looking for funding of about 3 Million USD for five years against 10% equity. These funds will be used for filing individual country patents, CRO trials, Regulatory requirements, Infrastructure development, and for marketing. We are open to negotiations if any investor is interested in investing a smaller amount.



ALS * +91-7505441858 * info@anupamlifesciences.com * www.anupamlifesciences.in



ROAD MAP -PRESENT



6 Months

We have filed patents all over the world. PCT has already been filed in 146 countries.

A US, Canada, Europe union and Indian patent were already filed.

12 Months

We will file all over the world in next year. we will file in countries such as Australia, New Zealand, South Africa, Singapore, Japan.



24 Months

We are outsourcing the marketing of one national pharma companies in each country keeping third-party manufacturing (approved by country-wise health authorities) under our control.



3RD YEAR

We will launch Jell/oil for physiotherapy.
Phase -3 trials completed and need clinical trials.
Bone Healer Phase -2 trials completed

6TH YEAR

Medicine for osteoporosis
Phase -2 Trials completed



10TH YEAR

Other Product Launch such as
1). Cure for Diabetes
(Phase 2 trial completed)
2). Converting HIV in chronic Disease
(Phase 2 trial completed)
3). Cure for Breast Cancer
(Phase 1 trial completed)

Cure of diabetes is the second product of choice for Anupam Lifescience with 100 billion dollar annual market



Product developed by:-

Anupam Herbals India www.anupamherbalsindia.com
For product details: see www.ah-osteocare.in



Dr. Anupam Gupta

3G-608, AWHO, Greater Noida, India

dranupam2009@gmail.com

(+91) - 7505441858

PROFESSIONAL QUALIFICATION

Masters in SURGERY (Orthopedics)	SNMC Agra, India	Aug 1994
M.B.B.S:	Sarojini Naidu Medical College (SNMC) Agra, India	Sep 1988

WORK EXPERIENCE SUMMARY

Specialist Orthopedics at Ministry of Interior [MOI], Saudi Arabia	Jan 2010 - Jan 2019
Consultant Orthopedics – Max group of hospitals, New Delhi	Jan 2009 - Dec 2009
Orthopedic Surgeon , Gupta Orthopedic Hospital, Budaun	Aug 1996 - Dec 2008
Research Associate , AIIMS, New Delhi	May 1995 - Aug 1996

WORK EXPERIENCE DETAILS

Specialist Orthopedics at Ministry of Interior [MOI], Saudi Arabia **Jan 2010 - Jan 2019**

Saudi Arabian Defense Hospital under the Ministry of Interior [MOI]. The Hospital Hospital for defense personnel only, mainly concerning Trauma cases.

Staff Coordinator - All CSH Hospitals

Reported Directly to the Supervisor General for all CSH Hospitals in Saudi Arabia, Ministry of Interior

Coordinated and supervised Medical Directors and Matasoft staff for betterment of all CSH

Monthly Evaluation of all the CSH hospitals

Implementation of protocol for chronic disease and progress evaluation

Evaluation and upgradation of hospital management system

Follow up of all memorandums issued by supervisory General Office

Chairman - Facility Management and Safety Committee

Chairman - Vitamin D Deficiency Program

Chairman - Morbidity and Mortality Committee

Co-Chairman - Education and Training Committee

Co-Chairman - Cardio-pulmonary Resuscitation Committee

Member - Multiple Committees

Speaker - Hyperuricemia, Vitamin D Deficiency, Recent Advancement in back Pain Management in individuals with Sedentary Lifestyle

Consultant Orthopedics - Max group of hospitals New Delhi **Jan 2009 - Dec 2009**

100 bedded ISO certificate Multi-specialty Hospital which was well known undisputed reputation in Delhi, India

Orthopedic Surgeon, Gupta Orthopedic Hospital, Budaun **Aug 1996 – Dec 2008**

Worked as Consultant Orthopedic Surgeon at Gupta Orthopedic center Jogipura Budaun

A 30 bedded Hospital under IMA Budaun (Indian Medical Association) where we dealt with patients of orthopedics, performing Out-patient care, In- Patient care, Operative work and Orthopedic research work.

Research Associate, AIIMS, New Delhi **May 1995 - Aug 1996**

Research associate at All India Institute Medical Sciences New Delhi, India. The job responsibilities included working as Registrar orthopedic along with conducting research in orthopedics.

To conduct special clinic independently like Scoliosis, CTEV, Hand surgery.

Good exposure of all kinds of surgeries from replacement to spine surgery. Extensive exposure of replacement Arthroplasties and revised Arthroplasties in failed cases[THR/TKR], Diagnostic and Therapeutic Arthroscopy, Ellizarove limb lengthening technique, Polio surgery like triple arthrodesis, TA lengthening etc.

Awards and Achievements:

Outstanding Performance and Lasting Contribution Award by General Supervisor of Ministry of Interior Hospitals	2012
Outstanding Performance and Lasting Contribution Award by General Supervisor of Ministry of Interior Hospitals	2013

CSH Jeddah was awarded Best CSH Hospital and chosen for a visit by Prince of KSA under his supervision as Medical Director 2010

Multiple awards for best employment among Medical Doctors

Medical Research and Development

www.anupamlifesciences.in

- 1) Developed local Painkiller for Osteoarthritis (Knee Pain) to eliminate the need for oral painkillers. The medicine has seen successful trials conducted by multiple MNCs in the Pharmaceuticals industry of India. Currently under marketing and negotiation for over 130 countries. Soon world patent applied at US Patent Office.
- 2) HIV Medicine. To convert fatal disease into a chronic disease. Helps a patient lead a life as normal as an individual untouched by AIDS. US Patent applied.
- 3) Cure of Diabetes. The medicine has seen a high success rate. The drug Protocol is under development.
- 4) Weight loss Medicine. Currently under trial.
- 5) Medicine which fasten bone union, Treatment of Perthes, Treatment of Osteomyelitis
- 6) Developed formulation for Cancer, which is effective in fourth stage of Cancer. Outstanding success in making bone free from secondary's and stop further Secondary's to develop. Extensive large scale trials required.
- 7) Developed medicine for Rheumatoid Arthritis.
- 8) Developed formulation for permanent contraceptive and six months contraceptive only by oral medicine. Under Trial in India
- 9) Develop medicine for Chronic Renal Failure. Under trial in India.

Appendix

For more information, please refer to the websites listed below:

1. AH-Osteocare:- www.ah-osteocare.in
2. Research House:- www.anupamherbalsindia.com
3. Anupam Life Sciences:- www.anupamlifesciences.in